Skip to content

Author

Y. Janjigian

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Re-evaluating the Role of Adjuvant Chemotherapy after Neoadjuvant Therapy in Resected Gastric Cancer.

BACKGROUND Perioperative chemotherapy is standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients with resectab...

Aravind Sreeram, Celine Yeh, N. Toumbacaris et al. · 0 citations
Open access Sep 2026

Neoadjuvant Chemoradiotherapy Versus Perioperative Chemotherapy ± Immunotherapy in Resectable Esophageal Adenocarcinoma.

OBJECTIVE We sought to compare pathologic responses, perioperative outcomes, and early survival between induction chemoradiotherapy and perioperative chemotherapy ± immunotherapy in patients with resectable esophageal adenocarcinoma. METHODS Using our prospectively maintained institutional database, we retrospectivel...

Aroub A. Alkaaki, Nian-Ye Zheng, N. Toumbacaris et al. · 0 citations
Open access Aug 2026

Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.

PURPOSE Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune feature...

Joseph J. Zhao, Choong-kun Lee, Allison S. Y. Chan et al. · 0 citations
Open access Aug 2026

The role of circulating tumor DNA (ctDNA) to detect minimal residual disease in locally advanced gastroesophageal carcinoma: the BUTTERFLY study

Background Despite advances in perioperative and neoadjuvant strategies, patients with locally advanced gastroesophageal cancers remain at high risk of recurrence after curative intent treatment. No validated biomarkers are available to detect minimal residual disease (MRD) or to guide post-operative risk-adapted manag...

A. Puccini, L. Paracchini, R. Alfieri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.